For most deep tech founders, the answer to early-stage funding is a SAFE. Because deep tech ventures run on long, unpredictable R&D cycles before any revenue exists, instruments that defer valuation and carry no maturity date give founders the timeline flexibility the sector demands. Convertible notes work as a bridge but import debt-like pressure that a five-year hardware development plan may not tolerate, while priced equity rounds make sense only once technical milestones justify a defensible valuation. This guide compares the three instruments on the dimensions that matter most to a science-based startup: dilution, control, and fit with long development timelines.
Introduction: Deep Tech's Unique Funding Landscape
Deep tech startups—ventures built on significant scientific or engineering innovation—do not follow the financing playbook written for software. The World Bank's analysis of deep tech financing observes that traditional funding models and cycles often fail to meet these companies' unique needs, because they generally don't follow a linear venture-stage investing process. Boston Consulting Group's investor guide reaches the same conclusion from the investor side: deep tech investments are "almost always risky and typically require more capital and greater patience than do other asset classes."
That patience requirement shapes every instrument choice a founder makes. A software startup can often reach a priced round within a year or two of launch; a company perfecting advanced hardware or novel materials may need several funding rounds just to mature the science and lock down a revenue-producing model, as Different Funds notes in its analysis of the deep tech deal funnel. The instrument you sign at pre-seed determines whether that extended runway is a strategic choice or a legal deadline.
Why Traditional Funding Models Fall Short for Deep Tech
The friction comes from two structural features of the sector. First, capital intensity: deep tech companies "can't be built in a basement over a weekend," in Different Funds' phrasing, and may require significantly more funding rounds than software startups to perfect the science and reach a revenue-producing business model. Second, milestone structure: as LenderKit's analysis of pre-commercialization investing explains, the appropriate milestones are often technical rather than commercial—reaching a performance target, completing a prototype, securing a patent, passing a regulatory milestone, or obtaining a pilot agreement can matter as much as revenue growth.
This mismatch hits hardest at the earliest stages. MIT's Orbit knowledge base notes that deep tech teams emerging from universities often turn first to equity-free grant funding, such as federal SBIR grants, precisely because traditional iterative startup techniques—define the customer, ship fast, learn in the market—don't apply when the solution itself is still under development. Investor evaluation also differs: LenderKit highlights that technical due diligence, examining the technology itself, is perhaps the clearest difference between deep tech and ordinary startup investing. Any funding instrument must therefore survive long technical uncertainty, not just market uncertainty.
Convertible Notes: Bridging Early Gaps
A convertible note is debt that typically converts to equity at a future priced round, usually carrying a discount and often a valuation cap, with interest that accrues over time. J.P. Morgan's comparison of early-stage instruments notes that maturity dates commonly run 12 to 24 months, and that repayment risk at maturity exists in principle if the note is not converted or extended. Dilution is deferred until conversion, and founders keep control in the interim—but the clock is always running.
That clock is the problem for deep tech. Carta's guidance on convertible securities lays out what happens if no qualifying financing occurs by maturity: founders and investors must negotiate an extension, convert at the valuation cap, or repay principal plus accrued interest in cash—and if the company cannot repay and has no clear path to conversion, bankruptcy becomes a risk. J.P. Morgan's founder-focused advice is blunt about the dynamic: a note approaching maturity without a financing event forces a negotiation the founder may not be positioned to win. For a venture whose prototype may take three years, a 24-month maturity is a strategic liability, and accrued interest increases the eventual conversion amount.
SAFEs: Flexibility for Unpredictable Journeys
A SAFE—a Simple Agreement for Future Equity—is not debt. It is a contractual right to equity in a future priced round, typically with a valuation cap or discount, but with no interest accrual and no maturity date. Carta notes that convertibles generally are faster, cheaper, and more flexible than priced rounds, and that SAFEs and notes are the two most common convertible securities startups use; SAFEs strip out the debt-like features that notes carry.
For deep tech, the absence of a maturity date is the decisive feature. Dilution is still deferred until conversion, exactly as with a note, but the founder controls the timing of the priced round rather than a contractual deadline controlling it. A team that needs an extra eighteen months to hit a technical milestone can take that time without facing a repay-or-extend negotiation from a position of weakness. The trade-off is that the ultimate dilution depends entirely on the future valuation and the caps and discounts negotiated now—J.P. Morgan's guidance warns founders to model what conversion looks like across every outstanding instrument before a priced round is imminent, treating dilution modeling as an ongoing discipline rather than a last-minute exercise.
Priced Equity Rounds: When Valuation Matters
A priced round sets a company valuation and issues shares at closing, establishing ownership percentages immediately. The clarity is real: J.P. Morgan's comparison shows ownership is established at signing, subject to standard closing adjustments, while both convertibles leave it deferred. Breaking Into Wall Street's technical guide to cap tables adds that priced rounds have become simpler and cheaper to execute, and they avoid the messy cap tables, unclear valuations, and accrued-interest dilution that deferred instruments can create—though the options pool is typically upsized in a priced round, adding its own dilution layer.
The costs are equally real. Priced rounds carry the highest upfront legal complexity of the three instruments, per J.P. Morgan, and require extensive negotiation over valuation—precisely the exercise a pre-revenue deep tech company is poorly positioned to win, since its value rests on unproven technology that demands technical due diligence. The strategic fit arrives later: once a venture has de-risked its technology through demonstrated milestones, a priced round converts technical progress into a defensible valuation and gives investors the governance clarity they typically require at larger check sizes.
Deep Tech Funding Instrument Decision Framework
The table below maps each instrument's core mechanics against the strategic challenges specific to deep tech: unpredictable development timelines, high capital needs, and the technical-milestone-driven path to a priced round.
| Funding Instrument | Key Mechanics (Valuation, Maturity, Interest) | Impact on Founder Control & Dilution | Suitability for Long R&D Cycles |
|---|---|---|---|
| Convertible Notes | Debt that converts at a future priced round; typically a discount and often a valuation cap; interest accrues; maturity date commonly 12–24 months, varying by agreement. | Dilution deferred until conversion, but repayment obligation exists at maturity if unconverted, and accrued interest increases the effective conversion amount. Maturity pressure can force premature or unfavorable financing. | Workable as a short bridge, but risky: if R&D outlasts the maturity date, founders face repay, extend, or convert-at-cap negotiations from a weak position. |
| SAFEs | Contractual right to future equity; typically a valuation cap and/or discount; no interest, no maturity date. | Dilution deferred until conversion, same as notes, but founders control the timing of the priced round. Ultimate dilution depends on future valuation and negotiated caps/discounts. | Strongest fit: no maturity deadline means technical milestones—not contract terms—dictate the pace toward the next round. |
| Priced Equity Rounds | Valuation set and shares issued at closing; price per share negotiated directly. | Dilution immediate and clearly defined; investors typically gain governance rights. Highest upfront legal complexity and negotiation burden. | Poor fit pre-milestone, when valuation is hard to justify; strong fit once technical de-risking supports a defensible valuation and larger capital needs. |
Read the table as a sequence, not just a menu. The framework that emerges: SAFEs dominate the earliest, most technically uncertain phase; notes serve only when a priced round is realistically within the maturity window; priced equity becomes the right instrument at the point where demonstrated technical progress can be converted into valuation. A typical deep tech path may therefore layer instruments over time rather than pick one—grant funding and SAFEs through the R&D phase, a priced round at the milestone that proves the science.
Strategic Funding for Deep Tech Success
Deep tech founders should prioritize funding instruments that offer flexibility in valuation and timeline, such as SAFEs, especially in early stages where R&D cycles are long and commercialization is distant. Priced rounds become more suitable once significant technical milestones are achieved and a clear valuation can be established. Convertible notes occupy a narrow middle ground: acceptable only when a priced round is realistically reachable before maturity, since the World Bank's finding that deep tech companies don't follow a linear venture-stage process means linear maturity assumptions are the first thing to break.
None of this is legal or financial advice, and dilution here is discussed conceptually rather than through cap table models—founders should model their specific conversion outcomes with counsel before signing. The measurable indicator of success is concrete: the startup successfully secures follow-on funding, such as a Series A, at a favorable valuation, demonstrating effective management of early-stage dilution and R&D timelines. Track that milestone—along with the technical achievements, whether a prototype, patent, or regulatory threshold, that make the valuation defensible—and let the instrument serve the science, not the other way around.
Sources
- Documents1
- WEB ASSETS
- The DeepTech Deal Funnel, Part 1: A Look at Venture Capital Funding - Different Funds
- Early-Stage Deep Tech Investing: How to Fund Companies Before Commercialization — LenderKit
- What is different about deep tech startups? — ORBIT KB
- How Convertible Notes Work for Startups & Founders — Jpmorgan
- Convertible Securities: SAFEs vs. Convertible Notes — Carta
- Convertible Notes for Startups: Full Guide + Excel File — Breaking Into Wall Street
